ALX Oncology Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ALX Oncology Holdings Inc. on December 17, 2021. The report details the entry into a material definitive agreement regarding the potential sale of the company's common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to raise up to $150 million through the sale of common stock.
Material Changes
- Sales Agreement Execution: On December 17, 2021, the Company entered into a Sales Agreement with Cantor Fitzgerald & Co. and Credit Suisse Securities (USA) LLC.
- Offering Structure: The agreement allows the Company to offer and sell shares of common stock from time to time through the Sales Agents in "at the market" offerings or negotiated transactions.
- Compensation: The Sales Agents are entitled to compensation of up to 3.0% of the gross sales price per share for shares sold under the agreement.
Guidance, Outlook, and Risks
The Company is not obligated to sell any shares under the Sales Agreement. The agreement may be suspended or terminated by either party upon written notice, including in the event of a material adverse change. The offering is subject to the terms of the Company's shelf registration statement on Form S-3, which became effective on August 13, 2021.
Key Facts for Investor Verification
- Verify the total number of shares sold and proceeds received under this Sales Agreement in subsequent filings.
- Monitor the Company's cash position and burn rate to assess the necessity of utilizing this $150 million facility.
- Review the prospectus supplement dated December 17, 2021, for specific terms regarding minimum sale prices and daily volume limitations.
- Check for any future 8-K filings indicating the suspension or termination of the Sales Agreement.